Tucatinib, trastuzumab, and capecitabine as second- or third-line therapy after trastuzumab deruxtecan in HER2-positive metastatic breast cancer: A multicenter retrospective study in France

The Breast · Elsevier

Аннотация

Publication date: December 2026 Source: The Breast, Volume 90 Author(s): JeanSebastien Frenel, Alexandre de Nonnevile, Catherine Guerin-Charbonnel, Jean Zeghondy, Laurent Mathiot, Audrey Mailliez, François Poumeaud, Nicolas Isambert, Monica Arnedos, Fanny Le Du, Loick Galland, Rayan Kabirian, Severine Guiu, Laura Poestch, Elise Deluche, François Cherifi, Florence Dalenc, Elsa Volant, Barbara Pistilli, Tevy San

Читать у издателя →

Похожие статьи